AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02403648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lilly Glucagon
Study NCT02403648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novo Glucagon
Study NCT02096640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Type of surgical teqnique for tracheostomy
Study NCT01130480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Integra Glucometer
Study NCT04514653 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab (anti-VEGF agent)
Study NCT04514653 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314 Dose 1
Description: AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
Study NCT04514653 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314 Dose 2
Description: AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
Study NCT04514653 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314 Dose 3
Description: AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
Study NCT04514653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Steroid
Description: Local steroid
Study NCT04514653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Steroid
Description: Topical steroid
Study NCT03551561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSAAC
Description: Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
Study NCT03551561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSAC
Description: Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
Study NCT03943654 — intervention group
Intervention type: OTHER
Intervention: MotoMeds Healthline- illness assessment and treatment recommendation for non-emergent cases by telephone
Description: The healthline uses a series of questions (based off of the WHO Integrated Management of Childhood Illness guidelines) asked to the parent of a sick child over the phone to remotely triage and assess the child's illness and then provide a treatment recommendation. MotoMeds is the accompanying motorcycle delivery service for basic medication delivery at nighttime.
Study NCT00406484 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard drug counseling
Description: Individual drug counseling
Study NCT00406484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BDRC
Description: Behavioral Drug and HIV Risk Reduction Counseling, individual once or twice weekly sessions
Study NCT02886455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive strip
Description: This is a standard adhesive strip (hydrocolloid)
Study NCT02886455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This a newly developed adhesive strip.
Study NCT03083834 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cosyntropin stimulation test
Description: At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.
Study NCT02426203 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary endarterectomy
Description: Echocardiographic assessment right ventricular function prior to, during, and following Pulmonary Endarterectomy surgery.
Study NCT01077076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zegerid
Description: Zegerid taken once daily for 11 days.
Study NCT01077076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilosec OTC™ Tablets
Description: Prilosec OTC™ Tablets taken once daily for 11 days.
Study NCT01077076 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken once daily for 11 days.
Study NCT01342159 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the bevacizumab group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30-gauge needle through the superotemporal quadrant. For the bevacizumab with triamcinolone group, in addition to intravitreal bevacizumab, 2 mg(0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally through the inferotemporal quadrant. For triamcinolone group, 2 mg (0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally.
Study NCT04782479 — intervention group
Intervention type: PROCEDURE
Intervention: hand position
Description: For tracheal intubation with a stylet for a manikin, one time, the position of the hand holding the tube was placed in the air, and the other time, the position of the hand holding the tube was placed on the cheek of the patient, while the assistant pulling back the stylet.
Study NCT04033016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: Motivational interviewing (MI) is a contemporary form of advisory support, which is often used for behavioral change. During the motivational interviewing educated health professional leads the counseling session by asking questions on lifestyle, attitude towards the behavioral change, and factors pro and against the change. During the MI the focus is on the patient/ client, his/her own perception of their health, understanding the reasons for current behavioral patterns, and encouragement to assess these patterns.
Study NCT04033016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online social media intervention
Description: Facebook group was specially designed for purposes of intervention and was administered by the research team. It was used to motivate the participants to be more physically active. The intervention used hybrid approach, with health promotion campaign with motivational messages and pictures, journal articles, questions with the aim to spark a discussion on barriers or possibilities for physical activity and participatory approach (all members were allowed to post motivational messages or questions for their peers).
Study NCT03710161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D taken in two different dosages daily for six months.
Study NCT03710161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D taken in two different dosages daily for six months.
Study NCT00125164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIGF-1 (mecasermin, Tercica, Inc.)
Description: Twice Daily Injection
Study NCT04238897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft contact lens
Study NCT04238897 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: soft contact lens
Study NCT00005080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Given IV
Study NCT02955849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLT laser
Description: Patients will be offered initial SLT laser by doctors
Study NCT03212313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tozadenant
Description: Two 60 mg tablets for a total single study dose of 120 mg
Study NCT03212313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant
Description: Two 60 mg tablets for a total single study dose of 120 mg
Study NCT00996333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Docetaxel, Capecitabine
Description: 1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11~This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles.
Study NCT00636493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fluocinolone acetonide (Retisert Implant)
Description: sustained release device consisting of 0.59 mg of fluocinolone acetonide
Study NCT04717219 — intervention group
Intervention type: OTHER
Intervention: Blood drawing
Description: Blood will be drawn after inclusion of the participants.
Study NCT03365349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: participating in a session of living theatre
Description: participating to a session of living theatre which consists in writing a story about life with diabetes, which is then transformed to a script to be played by professional actors co-directed by the patient with the support of the Director to create a short play
Study NCT03365349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: writing workshop
Description: one session consisting for the patient of writing a Letter to his/her own diabetes and then to read it to the group of patients and the healthcare providers.
Study NCT04312724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Socket TF
Description: The device is Class I, a low-risk product, and is a further development of a well-established technology. Össur Direct Socket (DS) technology has been on the market since 1996 (ICEX first generation) for the manufacture of leg prosthesis. This prosthetic socket for trans-femoral amputees (referred hereby to as DS-TF) has the same basic functional design as the Direct Socket (MSS) for trans-tibial amputees (referred hereby to as DS-TT) that is available on the market today in addition to the newly added silicon brim.~A prosthetic socket is a non-invasive, non-sterile, single user reusable device, which is used as part of prosthetic system. The aspect of the prosthesis that is in direct physical contact with the amputee is usually not the socket, to which a prosthesis is connected to, but the liner that serves as an interface between the amputee and the rest of the prosthesis. An amputee typically wears a prosthesis and thereby utilizes a socket, for up to 18 hours a day.
Study NCT04312724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Socket TF
Description: The device is Class I, a low-risk product, and is a further development of a well-established technology. Össur Direct Socket (DS) technology has been on the market since 1996 (ICEX first generation) for the manufacture of leg prosthesis. This prosthetic socket for trans-femoral amputees (referred hereby to as DS-TF) has the same basic functional design as the Direct Socket (MSS) for trans-tibial amputees (referred hereby to as DS-TT) that is available on the market today in addition to the newly added silicon brim.~A prosthetic socket is a non-invasive, non-sterile, single user reusable device, which is used as part of prosthetic system. The aspect of the prosthesis that is in direct physical contact with the amputee is usually not the socket, to which a prosthesis is connected to, but the liner that serves as an interface between the amputee and the rest of the prosthesis. An amputee typically wears a prosthesis and thereby utilizes a socket, for up to 18 hours a day.
Study NCT02506413 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MamaToto Package
Description: The MamaToto Package (later called Mama na Mtoto for the Tanzanian context) was an MNCH intervention built upon prior successes in Uganda and adapted to meet the needs in Misungwi District in Tanzania. The intervention included low-cost programming that built upon the existing district health system structure and resources in order to strengthen the MNH capacity and training of the district, health facilities, and community health workers.
Study NCT01258686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: 700mg thrice daily
Study NCT01258686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 700mg thrice daily
Study NCT04326803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B recombinant vaccine
Description: Administration of 20 mcg of hepatitis B recombinant vaccine im at month 0, 1 and 2
Study NCT03350672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TAF
Description: Participants in cohorts 1a\&b will be administered FTC/TAF for 1 to 7 consecutive days and then be followed clinically for 6 to 14 days. Cohort 2 will participate in a 1 time blood and urine collection.
Study NCT01911494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.
Study NCT01911494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyldopa
Description: Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.
Study NCT03614520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of olive oil
Description: 25 mL of extra virgin olive oil
Study NCT03614520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of red wine
Description: 150 mL or Red Wine
Study NCT03614520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of red wine and olive oil
Description: 150 mL of Red wine + 25 mL of Extra Virgin Olive oil will be administred at the same time
Study NCT03350672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TAF
Description: Participants in cohorts 1a\&b will be administered FTC/TAF for 1 to 7 consecutive days and then be followed clinically for 6 to 14 days. Cohort 2 will participate in a 1 time blood and urine collection.
Study NCT01444040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent inject
Description: Implantation of two iStent inject devices
Study NCT01444040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost
Description: Travoprost drops
Study NCT01795053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: playtraining
Description: playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and -intensity and thereby reduce ADHD symptoms
Study NCT01795053 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo open play session
Study NCT00478023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 20 mg IR; 4 - 6 hourly; Total 72 hours
Study NCT00478023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG5503 IR
Description: 50mg; 4 - 6 hourly; Total 72 hours
Study NCT00478023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG5503 IR
Description: 75mg; 4 -6 hourly; Total 72 hours
Study NCT00478023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG5503 IR
Description: 100mg, 4 - 6 hourly; Total 72 hours
Study NCT00478023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 - 6 hourly; Total 72 hours
Study NCT00378365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Arsenic trioxide
Study NCT00378365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATRA
Description: ATRA
Study NCT01809340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: In the 12-day open-label treatment phase, patients will self administer oral minocycline 200 mg on Day 1, 100 mg twice daily on Days 2 to 11, and 100 mg on the morning of Day 12. In the 6-week blinded treatment phase, responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first. In the 6-week open-label treatment phase, non-responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54).
Study NCT01809340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the 6-week blinded treatment phase, may self administer placebo twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first.
Study NCT01809340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: In the 12-day open-label treatment phase, all patients will receive 1 IV infusion of 0.5 mg/kg ketamine over 40 minutes on Days 1, 3, 5, 8, 10 and 12.
Study NCT01696539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Intervention
Description: Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
Study NCT01696539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
Study NCT01162642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Tea
Description: Green Tea 4 cups daily
Study NCT01162642 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 cups placebo tea for 6 weeks
Study NCT02377817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrenaBelt
Description: The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back or right side during sleep, it is expected to significantly decrease the amount of time she spends in these two positions via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PrenaBelt is worn at the level of the waist. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back and right side of the user when she lies on her back or right side, respectively, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back or right side.
Study NCT02377817 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PrenaBelt
Description: The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back or right side during sleep, it is expected to significantly decrease the amount of time she spends in these two positions via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PrenaBelt is worn at the level of the waist. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back and right side of the user when she lies on her back or right side, respectively, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back or right side.
Study NCT02377817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham PrenaBelt
Description: The Sham PrenaBelt and PrenaBelt are the same device except the plastic balls are removed from the Sham PrenaBelt so it cannot provide pressure points.
Study NCT02377817 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PrenaBelt
Description: The Sham PrenaBelt and PrenaBelt are the same device except the plastic balls are removed from the Sham PrenaBelt so it cannot provide pressure points.
Study NCT01320917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel releasing device
Description: LNG-IUD device releases levonorgestrel in circulation
Study NCT01320917 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cu-IUD insertion
Description: The action of a Cu-IUD does not release any hormonal compound
Study NCT04376866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: anti-PD-1 antibody
Study NCT02084407 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical examination, skin biopsy, blood and urine sampling
Study NCT03286517 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
Description: A neurohormone
Study NCT05755321 — intervention group
Intervention type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy performed during surgery.
Study NCT02457143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter